169 related articles for article (PubMed ID: 32461631)
21. Comparison of clinical and molecular characteristics of patients with acute myeloid leukemia and either TP73 or TP53 mutations.
Mims AS; Kohlschmidt J; Eisfeld AK; Mrόzek K; Blachly JS; Orwick S; Papaioannou D; Nicolet D; Sampath D; Stone RM; Powell BL; Kolitz JE; Byrd JC; Bloomfield CD
Leukemia; 2021 Apr; 35(4):1188-1192. PubMed ID: 32759975
[No Abstract] [Full Text] [Related]
22. Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.
Stein EM; DiNardo CD; Fathi AT; Mims AS; Pratz KW; Savona MR; Stein AS; Stone RM; Winer ES; Seet CS; Döhner H; Pollyea DA; McCloskey JK; Odenike O; Löwenberg B; Ossenkoppele GJ; Patel PA; Roshal M; Frattini MG; Lersch F; Franovic A; Nabhan S; Fan B; Choe S; Wang H; Wu B; Hua L; Almon C; Cooper M; Kantarjian HM; Tallman MS
Blood; 2021 Apr; 137(13):1792-1803. PubMed ID: 33024987
[TBL] [Abstract][Full Text] [Related]
23. TP-0903 is active in models of drug-resistant acute myeloid leukemia.
Jeon JY; Buelow DR; Garrison DA; Niu M; Eisenmann ED; Huang KM; Zavorka Thomas ME; Weber RH; Whatcott CJ; Warner SL; Orwick SJ; Carmichael B; Stahl E; Brinton LT; Lapalombella R; Blachly JS; Hertlein E; Byrd JC; Bhatnagar B; Baker SD
JCI Insight; 2020 Dec; 5(23):. PubMed ID: 33268594
[TBL] [Abstract][Full Text] [Related]
24. Single-cell mutation analysis of clonal evolution in myeloid malignancies.
Miles LA; Bowman RL; Merlinsky TR; Csete IS; Ooi AT; Durruthy-Durruthy R; Bowman M; Famulare C; Patel MA; Mendez P; Ainali C; Demaree B; Delley CL; Abate AR; Manivannan M; Sahu S; Goldberg AD; Bolton KL; Zehir A; Rampal R; Carroll MP; Meyer SE; Viny AD; Levine RL
Nature; 2020 Nov; 587(7834):477-482. PubMed ID: 33116311
[TBL] [Abstract][Full Text] [Related]
25. Second cancer incidence in CLL patients receiving BTK inhibitors.
Bond DA; Huang Y; Fisher JL; Ruppert AS; Owen DH; Bertino EM; Rogers KA; Bhat SA; Grever MR; Jaglowski SM; Maddocks KJ; Byrd JC; Woyach JA
Leukemia; 2020 Dec; 34(12):3197-3205. PubMed ID: 32704159
[TBL] [Abstract][Full Text] [Related]
26. Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts.
Zeidan AM; Boddu PC; Patnaik MM; Bewersdorf JP; Stahl M; Rampal RK; Shallis R; Steensma DP; Savona MR; Sekeres MA; Roboz GJ; DeAngelo DJ; Schuh AC; Padron E; Zeidner JF; Walter RB; Onida F; Fathi A; DeZern A; Hobbs G; Stein EM; Vyas P; Wei AH; Bowen DT; Montesinos P; Griffiths EA; Verma AK; Keyzner A; Bar-Natan M; Navada SC; Kremyanskaya M; Goldberg AD; Al-Kali A; Heaney ML; Nazha A; Salman H; Luger S; Pratz KW; Konig H; Komrokji R; Deininger M; Cirici BX; Bhatt VR; Silverman LR; Erba HP; Fenaux P; Platzbecker U; Santini V; Wang ES; Tallman MS; Stone RM; Mascarenhas J
Lancet Haematol; 2020 Aug; 7(8):e601-e612. PubMed ID: 32563283
[TBL] [Abstract][Full Text] [Related]
27. A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
Saygin C; Larkin K; Blachly JS; Orwick S; Ngankeu A; Gregory CT; Phelps MA; Mani S; Walker A; Garzon R; Vasu S; Walsh KJ; Bhatnagar B; Klisovic RB; Grever MR; Marcucci G; Byrd JC; Blum W; Mims AS
Am J Hematol; 2020 Dec; 95(12):1457-1465. PubMed ID: 32777116
[TBL] [Abstract][Full Text] [Related]
28. Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy.
Mato AR; Ghosh N; Schuster SJ; Lamanna N; Pagel JM; Flinn IW; Barrientos JC; Rai KR; Reeves JA; Cheson BD; Barr PM; Kambhampati S; Lansigan F; Pu JJ; Skarbnik AP; Roeker L; Fonseca GA; Sitlinger A; Hamadeh IS; Dorsey C; LaRatta N; Weissbrot H; Luning Prak ET; Tsao P; Paskalis D; Sportelli P; Miskin HP; Weiss MS; Svoboda J; Brander DM
Blood; 2021 May; 137(20):2817-2826. PubMed ID: 33259589
[TBL] [Abstract][Full Text] [Related]
29. Entospletinib in Combination with Induction Chemotherapy in Previously Untreated Acute Myeloid Leukemia: Response and Predictive Significance of
Walker AR; Byrd JC; Blachly JS; Bhatnagar B; Mims AS; Orwick S; Lin TL; Crosswell HE; Zhang D; Minden MD; Munugalavadla V; Long L; Liu J; Pan Y; Oellerich T; Serve H; Rao AV; Blum WG
Clin Cancer Res; 2020 Nov; 26(22):5852-5859. PubMed ID: 32820015
[TBL] [Abstract][Full Text] [Related]
30. Risk factors for grade 3/4 transaminase elevation in patients with chronic lymphocytic leukemia treated with idelalisib.
Brown JR; Zelenetz A; Furman R; Lamanna N; Mato A; Montillo M; O'Brien S; Dubowy R; Gu L; Munugalavadla V; Robak T; Hillmen P
Leukemia; 2020 Dec; 34(12):3404-3407. PubMed ID: 32655145
[No Abstract] [Full Text] [Related]
31. Pan-RAF inhibition induces apoptosis in acute myeloid leukemia cells and synergizes with BCL2 inhibition.
Tambe M; Karjalainen E; Vähä-Koskela M; Bulanova D; Gjertsen BT; Kontro M; Porkka K; Heckman CA; Wennerberg K
Leukemia; 2020 Dec; 34(12):3186-3196. PubMed ID: 32651543
[TBL] [Abstract][Full Text] [Related]
32. High Throughput Molecular Characterization of Normal Karyotype Acute Myeloid Leukemia in the Context of the Prospective Trial 02/06 of the Northern Italy Leukemia Group (NILG).
Salmoiraghi S; Cavagna R; Zanghì P; Pavoni C; Michelato A; Buklijas K; Elidi L; Intermesoli T; Lussana F; Oldani E; Caprioli C; Stefanoni P; Gianfaldoni G; Audisio E; Terruzzi E; De Paoli L; Borlenghi E; Cavattoni I; Mattei D; Scattolin A; Tajana M; Ciceri F; Todisco E; Campiotti L; Corradini P; Fracchiolla N; Bassan R; Rambaldi A; Spinelli O
Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32796597
[TBL] [Abstract][Full Text] [Related]
33. Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients.
Morsia E; McCullough K; Joshi M; Cook J; Alkhateeb HB; Al-Kali A; Begna K; Elliott M; Hogan W; Litzow M; Shah M; Pardanani A; Patnaik M; Tefferi A; Gangat N
Am J Hematol; 2020 Dec; 95(12):1511-1521. PubMed ID: 32833294
[TBL] [Abstract][Full Text] [Related]
34. Gene expression signature predicts relapse in adult patients with cytogenetically normal acute myeloid leukemia.
Walker CJ; Mrózek K; Ozer HG; Nicolet D; Kohlschmidt J; Papaioannou D; Genutis LK; Bill M; Powell BL; Uy GL; Kolitz JE; Carroll AJ; Stone RM; Garzon R; Byrd JC; Eisfeld AK; de la Chapelle A; Bloomfield CD
Blood Adv; 2021 Mar; 5(5):1474-1482. PubMed ID: 33683341
[TBL] [Abstract][Full Text] [Related]
35. The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia.
Alfayez M; Issa GC; Patel KP; Wang F; Wang X; Short NJ; Cortes JE; Kadia T; Ravandi F; Pierce S; Assi R; Garcia-Manero G; DiNardo CD; Daver N; Pemmaraju N; Kantarjian H; Borthakur G
Leukemia; 2021 Mar; 35(3):691-700. PubMed ID: 32561839
[TBL] [Abstract][Full Text] [Related]
36. Mutational spectrum and prognosis in NRAS-mutated acute myeloid leukemia.
Wang S; Wu Z; Li T; Li Y; Wang W; Hao Q; Xie X; Wan D; Jiang Z; Wang C; Liu Y
Sci Rep; 2020 Jul; 10(1):12152. PubMed ID: 32699322
[TBL] [Abstract][Full Text] [Related]
37. Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort.
Chiche E; Rahmé R; Bertoli S; Dumas PY; Micol JB; Hicheri Y; Pasquier F; Peterlin P; Chevallier P; Thomas X; Loschi M; Genthon A; Legrand O; Mohty M; Raffoux E; Auberger P; Caulier A; Joris M; Bonmati C; Roth-Guepin G; Lejeune C; Pigneux A; Vey N; Recher C; Ades L; Cluzeau T
Blood Adv; 2021 Jan; 5(1):176-184. PubMed ID: 33570629
[TBL] [Abstract][Full Text] [Related]
38. How I diagnose and treat NPM1-mutated AML.
Falini B; Brunetti L; Martelli MP
Blood; 2021 Feb; 137(5):589-599. PubMed ID: 33171486
[TBL] [Abstract][Full Text] [Related]
39. Incidence of venous thrombosis after peg-asparaginase in adolescent and young adults with acute lymphoblastic leukemia.
Underwood B; Zhao Q; Walker AR; Mims AS; Vasu S; Long M; Z Haque T; Blaser BW; Grieselhuber NR; Wall SA; Behbehani GK; Blachly JS; Larkin K; Byrd JC; Garzon R; Wang TF; Bhatnagar B
Int J Hematol Oncol; 2020 Sep; 9(3):IJH28. PubMed ID: 33014332
[TBL] [Abstract][Full Text] [Related]
40. Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With
Burchert A; Bug G; Fritz LV; Finke J; Stelljes M; Röllig C; Wollmer E; Wäsch R; Bornhäuser M; Berg T; Lang F; Ehninger G; Serve H; Zeiser R; Wagner EM; Kröger N; Wolschke C; Schleuning M; Götze KS; Schmid C; Crysandt M; Eßeling E; Wolf D; Wang Y; Böhm A; Thiede C; Haferlach T; Michel C; Bethge W; Wündisch T; Brandts C; Harnisch S; Wittenberg M; Hoeffkes HG; Rospleszcz S; Burchardt A; Neubauer A; Brugger M; Strauch K; Schade-Brittinger C; Metzelder SK
J Clin Oncol; 2020 Sep; 38(26):2993-3002. PubMed ID: 32673171
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
